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The study of fungal prion proteins affords remarkable oppor-
tunities to elucidate both intragenic and extragenic effectors of 
prion propagation. The yeast prion protein Sup35 and the self-
perpetuating [PSI+] prion state is one of the best characterized 
fungal prions. While there is little sequence homology among 
known prion proteins, one region of striking similarity exists 
between Sup35p and the mammalian prion protein PrP. This 
region is comprised of roughly five octapeptide repeats of similar 
composition. The expansion of the repeat region in PrP is associ-
ated with inherited prion diseases. In order to learn more about 
the effects of PrP repeat expansions on the structural properties of 
a protein that undergoes a similar transition to a self-perpetuating 
aggregate, we generated chimeric Sup35-PrP proteins. Using 
both in vivo and in vitro systems we described the effect of repeat 
length on protein misfolding, aggregation, amyloid formation 
and amyloid stability. We found that repeat expansions in the 
chimeric prion proteins increase the propensity to initiate prion 
propagation and enhance the formation of amyloid fibers without 
significantly altering fiber stability.
We recently described a novel chimeric prion system that was 
designed to elucidate the consequences of one class of inherited prion 
disease mutations on protein folding.1,2 We created a fusion between 
the mammalian prion protein PrP and the yeast prion protein 
Sup35p (Fig. 1). Sup35p is an essential translation termination factor 
in yeast. Interestingly, the majority of the protein can be sequestered 
into a self-propagating aggregate, the [PSI+] prion.3 Remarkably, 
when yeast are grown in normal laboratory conditions, the [PSI+] 
prion is not detrimental. In fact, the biological consequences of the 
switch from the [psi-] non-prion state to the [PSI+] prion state may 
be beneficial in terms of adaptation and evolution.4 Importantly, the 
prion state of Sup35p can be readily detected in vivo by monitoring 
the reduced function of the translation termination factor when the 
protein is propagating as a prion aggregate.3 In addition, several 
methods have been developed to not only follow the propagation 
of the prion, but also to control the propagation and promote prion 
induction and loss (curing).5 Therefore, in addition to simply being 
a fascinating biological problem in of itself, the [PSI+] prion in yeast 
affords the ability to further elucidate both intragenic and extragenic 
effectors of prion biology.
Several prions have now been identified and interestingly, there is 
little sequence homology between the proteins to suggest that only 
one type of sequence can form a self-propagating aggregate.6-8 In 
vitro studies suggest that many proteins can form amyloids under 
the appropriate conditions.9 The fact that only a small percentage of 
proteins propagate as prions in vivo may be partly a consequence of 
physiological conditions being adequate to promote amyloid forma-
tion with those particular sequences. It is unclear what the precise 
distinction between prion and amyloid is at this time, but localiza-
tion alone may preclude some amyloidogenic proteins from being 
“prion proteins” per se.10
The sequence context that permits a protein to adopt a prion 
conformation in vivo is unclear. Several of the identified prion 
proteins have a domain that is enriched in glutamine and asparagine 
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Figure 1. Schematic representation of the yeast protein Sup35p and the 
mammalian prion protein PrP highlighting the position of the oligopeptide 
repeat domain (ORD). The amino acid sequence represents the consensus 
for a single repeat. Numbers shown represent the amino acid position of 
the beginning and the end of each ORD. The numbers above the schematic 
represent the original PrP amino acid positioning and the numbers below 
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Repeat expansions in Sup35-PrP chimeric prion proteins
In our in vivo study,1 we highlighted a unique feature of the 
longest Sup35-PrP chimera that related to the ability of the protein 
to adopt multiple self-perpetuating prion conformations more readily 
than wild type Sup35p. We suggest that this may be an important 
aspect of prion biology as it relates to inherited disease. If the repeat-
expanded proteins can adopt multiple conformations that aggregate, 
then that may contribute to the large amount of variation observed 
in pathology and disease progression in this class of inherited prion 
diseases.21,22
We also found that the spontaneous conversion of the repeat-
expanded Sup35-PrP chimera into a prion state was significantly 
increased. However, this conversion required another aggregated 
protein in vivo, the [RNQ+] prion. In vitro, the prion-forming 
domain of the chimera showed a similar trend with the longer repeat 
lengths enhancing the ability of the protein to form amyloid fibers. 
The chimera with repeat expansions (8, 11 or 14 repeats) formed 
fibers very quickly as compared to that with the wild type number 
of repeats (5). While this correlates with the in vivo data in that 
both systems demonstrate an increased level of conversion with the 
repeat expansion, the systems are very different with respect to their 
requirement for a different “seed” to initiate the prion conversion. 
So, how does the [RNQ+] prion influence [PSI+]? At the moment, 
that isn’t entirely clear. Susan Liebman and colleagues discovered 
another epigenetic factor in yeast, [PIN+], which was important for 
the de novo induction of [PSI+].23-25 Several years later, the [RNQ+] 
prion26 was found to be that factor in the commonly used [PSI+] 
laboratory strains, but they also found that the overexpression of 
other proteins could reproduce the effect.25 Hence, [RNQ+] can 
be [PIN+], and may be the primary epigenetic element that influ-
ences [PSI+] induction in yeast, but need not be in every case. Two 
models were proposed to explain the ability of [RNQ+] to influence 
the induction of [PSI+].25,27 One suggested that there is a direct 
templating effect where the aggregated state of the Rnq1 protein in 
the [RNQ+] prion serves as a seed for the direct physical association 
and aggregation of Sup35p and initiates [PSI+]. The second postu-
lated that there is an inhibitor of aggregation in cells that is titrated 
out by the presence of another aggregated protein. Recent experi-
mental evidence suggests that the templating model may explain 
at least part of the mechanism of action behind the [RNQ+] prion 
inducing the formation of [PSI+].28,29
Why is [RNQ+] required for the in vivo conversion of the repeat-
expanded chimera that forms amyloid on its own very efficiently in 
vitro? Interestingly, we found that the [RNQ+] prion per se is not 
required. We overexpressed the Rnq1 protein from a constitutive 
high promoter (pGPD-RNQ1) and found that Rnq1p aggregated in 
the cells but did not induce the [RNQ+] prion. That is, the cells were 
still [rnq-] and did not genetically transmit the aggregated state of the 
protein. However, even these non-prion aggregates of Rnq1p served 
to enhance the induction of the chimeric prions. Therefore, either the 
[RNQ+] prion or an aggregate of Rnq1 protein is sufficient, which 
is in line with previous studies that demonstrated that some proteins 
that aggregate when overexpressed can also enhance the induction 
of [PSI+].25 Also of note, recent data suggests that the requirement 
of [RNQ+] for the induction of Sup35p aggregation in vivo can be 
overcome by very long polyglutamine or glutamine/tyrosine stretches 
fused to the non-prion forming domain of Sup35p.30 These fusions 
may alter protein-protein interactions or destabilize the non-prion 
(Q/N) residues, but this is not true of all prion proteins.7 Our recent 
study demonstrates that the Q/N character of the Sup35p prion-
forming domain can be significantly reduced, yet still propagate as a 
prion.1 This was also found recently in another prion protein chimera 
created and expressed in yeast.6 These studies suggest that the lack 
of stable secondary structure may be one of the defining features of 
a prion-forming domain. One of the striking sequence similarities 
that does exist between two prion proteins occurs in an oligopep-
tide repeat region found in Sup35p and PrP.11 Previous data clearly 
demonstrated that the Sup35p repeats are important for [PSI+] prion 
propagation.12-15 The deletion of a single repeat from the wild type 
SUP35 sequence results in the loss of normal [PSI+] prion propa-
gation.12 Moreover, the addition of two extra repeats of Sup35p 
sequence served to enhance the formation of the [PSI+] prion.13 The 
expansion of the analogous repeat domain in the mammalian prion 
protein PrP is associated with an inherited form of prion disease.16 
Since the repeat regions of Sup35p and PrP are similar in size and 
character, we wanted to determine if the Sup35p oligopeptide repeat 
region could be substituted with that of PrP. Indeed, the PrP repeats 
in the context of Sup35p supported the propagation of the [PSI+] 
prion in yeast.1,17 Strikingly, we found phenotypic changes that 
occurred in a repeat length-dependent manner that suggested that 
the repeat expansions associated with disease result in an increase in 
the aggregation propensity but do not necessarily dictate only one 
type of aggregate structure.1
More recently, we verified some of these results in vitro.2 These 
data are in agreement with other studies on the effect of repeat expan-
sions.18,19 Taking the analysis one step further, we demonstrated that 
the stability of the amyloid fibers formed with the repeat-expanded 
proteins did not differ significantly. A very interesting observation 
that we made was that the formation of amyloid fibers by the longest 
repeat-expanded chimera (SP14NM) followed drastically different 
kinetics compared to the chimera containing the wild type number 
of repeats (SP5NM).2 In unseeded reactions, SP14NM did not show 
a lag phase during the course of fiber formation whereas SP5NM 
displayed a characteristic lag phase. Furthermore, the morphology of 
the amyloid fibers visualized by EM was different between SP14NM 
and SP5NM. SP14NM fibers were curvy and clumped but SP5NM 
fibers were long and straight. The correlation between the kinetics 
and the morphology of amyloid formation of SP14NM and SP5NM 
is reminiscent of fibers formed by β2-microglobulin (β2m) protein 
in different conditions.20 At pH 3.6, β2m formed curvy, worm-like 
fibers with no apparent lag phase. In contrast, long, straight fibers 
were formed at pH 2.5 and had a distinct lag phase. Analysis of the 
β2m fibers formed at pH 3.6 using mass spectrometric techniques 
identified species ranging from monomer to 13-mer. This suggested 
that the fibers were formed by monomer addition. On the other 
hand, oligomers larger than tetramers were not formed during 
fiber formation at pH 2.5. Based on these data the authors propose 
that β2m forms fibers in a nucleation-independent manner at pH 
3.6, but fiber formation at pH 2.5 follows a nucleation-dependent 
mechanism. We suggest that the mechanism underlying SP5NM and 
repeat-expanded SP14NM fiber formation is similar to β2m fibers 
formed at pH 2.5 and pH 3.6, respectively. It will be interesting to 
determine if disease-associated mutations in amyloidogenic proteins 
alter the pathway whereby amyloid formation occurs and how that 
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structure of Sup35p in such a manner that the [RNQ+] prion seed 
is no longer required to form [PSI+] de novo. Indeed, the non-
polymerizing state of some of the fusion proteins was shown to be 
very unstable.
So, what is the important difference between our in vitro and 
in vivo systems in the prion conversion? Obviously there are many 
candidates. First, the full length Sup35 protein may alter the conver-
sion properties since a large part of the molecule is the structured C 
terminal domain. The C terminal domain may influence the initia-
tion of prion propagation in vivo and that is not a factor in the in vitro 
system. Second, the influences of co-translational folding and poten-
tially some initial unfolding of the prion-forming domain are not 
present since the in vitro system starts with denatured protein. Third, 
the environmental influences are clearly different. The molecular 
crowding effects and chaperones that are required for prion propaga-
tion in vivo are not required for the formation of amyloid in vitro. 
Finally, it is unclear if amyloid structures similar to those formed with 
the prion-forming domain in vitro actually exist in yeast. Certainly 
there is some correlation between the structures since aggregated 
Sup35 protein from [PSI+] cell lysates can seed amyloid formation 
in vitro31,32 and the fibers formed in vitro can be transformed into 
[psi-] cells and cause conversion to [PSI+].33 Nevertheless, we find it 
interesting that the expansion of the repeat region can have a tremen-
dous effect on amyloid formation in vitro yet still cannot overcome 
the requirement for [RNQ+] for conversion in vivo. The presence 
of co-aggregating or cross-seeding proteins may play a role in the 
sporadic appearance or progression of neurodegenerative diseases and 
the interconnected yeast prions [RNQ+] and [PSI+] may provide a 
model system for elucidating the mechanism underlying such effects.
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